venous%20thromboembolism%20-%20management
VENOUS THROMBOEMBOLISM - MANAGEMENT
Deep vein thrombosis is a frequent manifestation of venous thromboembolism in which there is a blood clot blocking a deep vein.
Clinical findings are important to the diagnosis of deep vein thrombosis but are poor predictors of the presence or severity of thrombosis.
Pulmonary embolism is the blockage of the blood vessels in the lungs usually due to blood clots from the veins, especially veins in the legs and pelvis.
Dyspnea, pleuritic chest pain, syncope and tachypnea occur in most cases of pulmonary embolism.
Massive pulmonary embolism has the prime symptom of dyspnea and systemic arterial hypotension that requires pressor support is the predominant sign.
Drug Information

Indication: DVT & pulmonary embolism (PE). Prevention of stroke & systemic embolism in adult patients w/ non-valvu...

Indication: 75-mg & 110-mg cap: Primary prevention of venous thromboembolic events in adult patients who have undergon...

Indication: Thrombolytic treatment in acute MI (AMI): 90-min (accelerated) dose regimen for patients in whom treatment can...

Indication: Prevention of venous thromboembolic events (VTE) in patients undergoing major orthopaedic surgery of the lower...

Cardin
aspirin + glycine

Indication: Transient ischaemic attacks, secondary prevention of MI. Prophylaxis against stroke, vascular occlusion & ...

Indication: Transient ischaemic attacks, secondary prevention of MI. Platelet aggregation inhibitor for prophylaxis agains...

Indication: AMI. Prevention of heart attack in certain high-risk patients; prevention of CVA after transient ischaemic att...

Indication: 10-mg tab Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replace...

1  /  2
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.